Off-Patent Therapy Restores Brain Connectivity in Multiple Sclerosis
Clinical imaging demonstrates that N-acetylcysteine repairs neural functional networks damaged by oxidative stress
Administering an off-patent compound alongside standard care improves functional brain connectivity in people with multiple sclerosis. Investigators at Thomas Jefferson University reported the clinical imaging results in IBRO Neuroscience Reports, identifying a treatment route that addresses nerve cell damage. The therapeutic protocol relies on replenishing depleted antioxidant defenses within the central nervous system.
Targeting oxidative pathways with an established compound
Existing regimens for multiple sclerosis concentrate on suppressing the hyperactive immune responses that harm patient vision, coordination and cognitive capacity. A research team at Thomas Jefferson University evaluated a complementary approach utilizing N-acetylcysteine, an inexpensive drug whose initial patent protections lapsed decades ago, according to MedicalXpress.
The molecule stimulates synthesis of glutathione, a vital antioxidant that naturally defends neural tissue against cellular stress. Multiple sclerosis patients regularly exhibit diminished concentrations of this critical molecule. "Every hospital has it," explained Daniel Monti, chair of the Department of Integrative Medicine and Nutritional Sciences, in remarks reported by MedicalXpress. Monti pointed out that emergency clinicians already administer the drug to treat liver damage caused by acetaminophen toxicity.
“Multiple sclerosis is breaking connections and NAC helps reestablish them. In short, it helps the brain work better.”
— Andrew Newberg, M.D., Thomas Jefferson University
Positron emission tomography verifies network repair
Earlier pilot evaluations demonstrated symptomatic relief, including reduced physical fatigue, lessened anxiety and clearer thinking. To track physiological changes directly, scientists conducted brain evaluations using positron emission tomography, as detailed by MedicalXpress.
The resulting scans revealed stronger functional connectivity, demonstrating that disparate cerebral regions resumed synchronized communication. This medical innovation relies on the molecule's proven ability to cross the blood-brain barrier with minimal side effects. Andrew Newberg, director of the PET and MRI imaging program at Jefferson, confirmed to MedicalXpress that the treatment helps mend disrupted neural circuits.
Broader neurological testing and clinical horizons
Because generic manufacturers produce the substance without restrictive patents, clinical deployment remains highly cost-effective across public healthcare systems. Laboratory evidence published in IBRO Neuroscience Reports suggests the antioxidant mechanism may also benefit conditions such as Parkinson's disease.
The investigators confirmed that expanded clinical trials are needed to define standard dosing schedules. Monti plans to evaluate the molecule in patients recovering from traumatic brain injury, as reported by MedicalXpress.
Read also on The Patent: Rockefeller University Engineers TrUDI Platform for Deep Brain Imaging · Subcortical Nuclei Anticipate Sensory Sights and Touch in Real Time
